You are here: Home » B2B Connect » Budget » News
Business Standard

Viewing the Indian pharma sector through the biosimilar lens

Budget is expected to provide certain incentives to promote innovation & in-house R&D in the sector

Prof V K Unni 

The Indian pharmaceutical market which would rank amongst the top five in terms of volume is also the largest provider of generic drugs globally. This has earned India the sobriquet “pharmacy of the developing world”. It is estimated that Indian pharmaceutical companies supply around 80 per cent of the antiretroviral drugs that are being used on a global scale to deal with AIDS.  The sector, which is valued at around $ 35 billion, is expected to cross $ 50 billion by 2019-20. This sector also attracts considerable Foreign Direct Investment (FDI) with inflows ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital

Viewing the Indian pharma sector through the biosimilar lens

Budget is expected to provide certain incentives to promote innovation & in-house R&D in the sector

Budget is expected to provide certain incentives to promote innovation & in-house R&D in the sector The Indian pharmaceutical market which would rank amongst the top five in terms of volume is also the largest provider of generic drugs globally. This has earned India the sobriquet “pharmacy of the developing world”. It is estimated that Indian pharmaceutical companies supply around 80 per cent of the antiretroviral drugs that are being used on a global scale to deal with AIDS.  The sector, which is valued at around $ 35 billion, is expected to cross $ 50 billion by 2019-20. This sector also attracts considerable Foreign Direct Investment (FDI) with inflows ... image
Business Standard
177 22

Viewing the Indian pharma sector through the biosimilar lens

Budget is expected to provide certain incentives to promote innovation & in-house R&D in the sector

The Indian pharmaceutical market which would rank amongst the top five in terms of volume is also the largest provider of generic drugs globally. This has earned India the sobriquet “pharmacy of the developing world”. It is estimated that Indian pharmaceutical companies supply around 80 per cent of the antiretroviral drugs that are being used on a global scale to deal with AIDS.  The sector, which is valued at around $ 35 billion, is expected to cross $ 50 billion by 2019-20. This sector also attracts considerable Foreign Direct Investment (FDI) with inflows ...

image
Business Standard
177 22